CRDMO BioDuro and Atombeat have announced a strategic collaboration on an AI powered platform for accelerated peptide drug discovery. 

The collaboration brings together Atombeat’s in silico modeling, AI-accelerated and data-driven design platform with BioDuro’s discovery chemistry, biology and DMPK. 

The combined platform aims to deliver high quality cyclic peptides with faster timelines and better economy across a broad range of therapeutic areas. 

Atombeat’s Hermite software and RiDYMO platform uses technologies such as Reinforced Dynamics, Uni-Dock, Uni-FEP, and Uni-QSAR, combining computer modelling, artificial intelligence, and specialised data to explore a digital library of over one trillion potential peptide compounds. 

BioDuro uses its high-throughput synthesis capability to produce hundreds of peptide compounds in parallel. 

“We are excited to advance peptide innovation through our strategic partnership with Atombeat. Atombeat brings extensive experience in AI-assisted drug design and optimization,” said Dr Armin Spura, CEO of BioDuro. “Together, we aim to provide the industry with leading services in peptide drug development, accelerating smarter and more efficient peptide research, and delivering faster and comprehensive solutions to our global clients.” 

“BioDuro’s deep expertise in peptide synthesis and testing complements our strengths in AI-driven drug design exceptionally well,” added Dr Dongdong Wang, Co-Founder of Atombeat. “By integrating AI with experimental processes, we are committed to building an intelligent, integrated platform for peptide drug discovery and evaluation. Our shared commitment is to drive innovation in pharmaceutical development and help meet unmet clinical needs worldwide.”

Diana Turner, Senior Digital Content Editor, DDW